Summary & Overview
HCPCS Level II S9988: Phase I Clinical Trial Services
HCPCS Level II code S9988 denotes services provided as part of a Phase I clinical trial. The code captures clinical trial–related patient care and research activities during early-stage human studies, which are critical for assessing safety, dosing, and feasibility of new therapies. Nationally, accurate reporting of such services supports research billing transparency, appropriate reimbursement pathways, and consistent documentation for trial sponsors and payers.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of the code’s clinical application, typical sites of service, common billing modifiers, and where this code fits in research billing workflows. The publication also provides context on payer coverage considerations and coding practice implications relevant to hospitals, academic research centers, and outpatient research clinics.
This summary equips billing and compliance teams, clinical trial administrators, and policy analysts with a clear reference for S9988 — what it represents, why it matters in the clinical research and reimbursement ecosystem, and the main topics covered in the full publication (benchmarks, policy updates, and clinical context).
Billing Code Overview
HCPCS Level II code S9988 represents services provided as part of a phase I clinical trial. This code is used to report activities and care directly associated with participation in a Phase I research study.
-
Service type: Clinical trial services and research-related patient care
-
Typical site of service: Hospital outpatient departments, academic medical centers, specialized research clinics, and other settings conducting Phase I clinical trials
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic solid tumor is enrolled in a Phase I clinical trial evaluating a novel targeted therapy. The patient presents to the clinical research unit for initial trial screening and first-cycle administration. Workflow includes informed consent review, eligibility confirmation (laboratory tests, ECG, performance status), baseline imaging orders, placement of an IV or port access, study drug administration per protocol, and safety monitoring for adverse events during the observation period. Documentation captures study name/identifier, protocol phase, investigational drug dosing, time spent on trial-specific procedures, and any trial-specific assessments. Billing for non-routine services provided as part of the Phase I trial is reported under S9988 when allowed by payer policy, with appropriate modifiers applied for unusual circumstances (e.g., increased procedural services, credentialing modifiers for research staff, or anesthesia-related modifiers). Typical sites of service include an academic medical center, hospital outpatient department, or designated clinical research unit within the hospital or cancer center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resource intensity substantially exceeds usual for the service during trial-related procedures. |